灵康药业：2025年半年度净利润约-3573万元

Core Viewpoint - Lingkang Pharmaceutical reported a year-on-year increase in revenue for the first half of 2025, but continued to experience net losses [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 172 million yuan, representing a 21.3% increase compared to about 141 million yuan in the same period of 2024 [2] - The net loss attributable to shareholders for the first half of 2025 was approximately 35.73 million yuan, an improvement from a net loss of about 40.40 million yuan in the first half of 2024 [2] - Basic earnings per share for the first half of 2025 were a loss of 0.05 yuan, compared to a loss of 0.06 yuan in the same period of 2024 [2]